Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$293.81−7.90 (-2.62%)
Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –
Ligand Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Ligand Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2026 was 10.1%. For fiscal 2025 it was 15.3%, against -13.5% the year before. The highest annual figure on record is 671.0% in fiscal 2019.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15.3% | +28.8 |
| FY2024 | Dec 31, 2024 | -13.5% | −22.6 |
| FY2023 | Dec 31, 2023 | 9.1% | +7.5 |
| FY2022 | Dec 31, 2022 | 1.5% | −41.4 |
| FY2021 | Dec 31, 2021 | 43.0% | +20.1 |
| FY2020 | Dec 31, 2020 | 22.9% | −648.1 |
| FY2019 | Dec 31, 2019 | 671.0% | +605.9 |
| FY2018 | Dec 31, 2018 | 65.1% | +16.9 |
| FY2017 | Dec 31, 2017 | 48.2% | +8.0 |
| FY2016 | Dec 31, 2016 | 40.3% | +2.3 |
| FY2015 | Dec 31, 2015 | 38.0% | +7.6 |
| FY2014 | Dec 31, 2014 | 30.4% | −0.1 |
| FY2013 | Dec 31, 2013 | 30.5% | +29.9 |
| FY2012 | Dec 31, 2012 | 0.6% | +3.5 |
| FY2011 | Dec 31, 2011 | -2.9% | +121.6 |
| FY2010 | Dec 31, 2010 | -124.5% | −98.9 |
| FY2009 | Dec 31, 2009 | -25.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -20.0% | −68.0 |
| Q2 FY2026 | Jun 30, 2026 | 13.5% | −4.2 |
| Q1 FY2026 | Mar 31, 2026 | 33.6% | +113.5 |
| Q4 FY2025 | Dec 31, 2025 | 25.7% | +48.2 |
| Q3 FY2025 | Sep 30, 2025 | 48.0% | +41.9 |
| Q2 FY2025 | Jun 30, 2025 | 17.7% | +63.7 |
| Q1 FY2025 | Mar 31, 2025 | -79.9% | −89.5 |
| Q4 FY2024 | Dec 31, 2024 | -22.5% | −10.6 |
| Q3 FY2024 | Sep 30, 2024 | 6.1% | −3.3 |
| Q2 FY2024 | Jun 30, 2024 | -46.0% | −38.5 |
| Q1 FY2024 | Mar 31, 2024 | 9.6% | −22.7 |
| Q4 FY2023 | Dec 31, 2023 | -11.9% | +27.9 |
| Q3 FY2023 | Sep 30, 2023 | 9.4% | −11.5 |
| Q2 FY2023 | Jun 30, 2023 | -7.5% | −24.8 |
| Q1 FY2023 | Mar 31, 2023 | 32.3% | +26.5 |
| Q4 FY2022 | Dec 31, 2022 | -39.9% | −106.7 |
| Q3 FY2022 | Sep 30, 2022 | 20.8% | −5.5 |
| Q2 FY2022 | Jun 30, 2022 | 17.3% | −40.7 |
| Q1 FY2022 | Mar 31, 2022 | 5.8% | −4.3 |
| Q4 FY2021 | Dec 31, 2021 | 66.8% | +34.2 |
| Q3 FY2021 | Sep 30, 2021 | 26.3% | +17.4 |
| Q2 FY2021 | Jun 30, 2021 | 58.0% | +40.9 |
| Q1 FY2021 | Mar 31, 2021 | 10.1% | −1.3 |
| Q4 FY2020 | Dec 31, 2020 | 32.7% | +70.4 |
| Q3 FY2020 | Sep 30, 2020 | 9.0% | +29.7 |
| Q2 FY2020 | Jun 30, 2020 | 17.1% | +33.7 |
| Q1 FY2020 | Mar 31, 2020 | 11.4% | −1889.4 |
| Q4 FY2019 | Dec 31, 2019 | -37.7% | −93.3 |
| Q3 FY2019 | Sep 30, 2019 | -20.8% | −72.0 |
| Q2 FY2019 | Jun 30, 2019 | -16.5% | −94.5 |
| Q1 FY2019 | Mar 31, 2019 | 1900.8% | +1834.8 |
| Q4 FY2018 | Dec 31, 2018 | 55.6% | +8.1 |
| Q3 FY2018 | Sep 30, 2018 | 51.2% | +15.0 |
| Q2 FY2018 | Jun 30, 2018 | 77.9% | +63.5 |
| Q1 FY2018 | Mar 31, 2018 | 66.0% | +47.8 |
| Q4 FY2017 | Dec 31, 2017 | 47.6% | −3.1 |
| Q3 FY2017 | Sep 30, 2017 | 36.1% | – |
| Q2 FY2017 | Jun 30, 2017 | 14.5% | – |
| Q1 FY2017 | Mar 31, 2017 | 18.2% | – |
| Q4 FY2016 | Dec 31, 2016 | 50.7% | – |
See a number that looks wrong?